Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures

Tomoko Tetsunaga, Tomonori Tetsunaga, Keiichiro Nishida, Masato Tanaka, Yoshihisa Sugimoto, Tomoyuki Takigawa, Yoshitaka Takei, Toshihumi Ozaki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction Denosumab specifically inhibits the receptor activator for nuclear factor-kappa B ligand (RANKL), and prevents osteoporotic fractures. Several reports have analyzed the effects of denosumab and alendronate alone on bone mineral density (BMD) or reduction of fracture risk. The objective of this study was to analyze the effects of antiresorptive osteoporosis pharmacotherapy on pain relief in patients with fresh vertebral fracture. Methods This retrospective, single-center study included 80 patients (10 males, 70 females) with fresh osteoporotic vertebral fractures treated using denosumab at a dose of 60 mg subcutaneously every 6 months (40 patients) or alendronate at a dose of 35 mg orally every week (40 patients) for 6 months in our hospital. The mean age of subjects was 77 years (range, 55–92 years). The primary outcome was duration of back pain. Secondary outcomes included changes in BMD, serum type 1 collagen cross-linked N-telopeptide (NTX), and serum N-terminal propeptide of type 1 collagen (P1NP) from baseline to 6 months. Pain catastrophizing due to back pain was assessed using the Pain Catastrophizing Scale (PCS). The incidences of further vertebral fracture and adverse events were also assessed. Results Pain relief was obtained at a mean of 3.3 weeks with denosumab and 5.4 weeks with alendronate. Pain relief was achieved significantly earlier with denosumab than with alendronate. At 6 months, change in BMD was higher with denosumab (6.1%) than with alendronate (0.8%). No significant differences in changes in NTX and P1NP were observed between groups. Scores for PCS were significantly lower for denosumab than for alendronate. The incidence of further vertebral fractures was 5% with denosumab and 10% with alendronate. Adverse event rates were similar between groups. Conclusions Denosumab enabled earlier pain relief than alendronate and avoided catastrophizing in patients with osteoporotic vertebral fractures after 6 months of treatment.

Original languageEnglish
Pages (from-to)230-236
Number of pages7
JournalJournal of Orthopaedic Science
Volume22
Issue number2
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Alendronate
Osteoporotic Fractures
Back Pain
Catastrophization
Bone Density
Pain
Therapeutics
Collagen Type I
RANK Ligand
Denosumab
Fracture Fixation
Incidence
Risk Reduction Behavior
Serum
Osteoporosis
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Orthopedics and Sports Medicine

Cite this

Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures. / Tetsunaga, Tomoko; Tetsunaga, Tomonori; Nishida, Keiichiro; Tanaka, Masato; Sugimoto, Yoshihisa; Takigawa, Tomoyuki; Takei, Yoshitaka; Ozaki, Toshihumi.

In: Journal of Orthopaedic Science, Vol. 22, No. 2, 01.03.2017, p. 230-236.

Research output: Contribution to journalArticle

@article{777502e7205144d8bf9c42ee98583cdb,
title = "Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures",
abstract = "Introduction Denosumab specifically inhibits the receptor activator for nuclear factor-kappa B ligand (RANKL), and prevents osteoporotic fractures. Several reports have analyzed the effects of denosumab and alendronate alone on bone mineral density (BMD) or reduction of fracture risk. The objective of this study was to analyze the effects of antiresorptive osteoporosis pharmacotherapy on pain relief in patients with fresh vertebral fracture. Methods This retrospective, single-center study included 80 patients (10 males, 70 females) with fresh osteoporotic vertebral fractures treated using denosumab at a dose of 60 mg subcutaneously every 6 months (40 patients) or alendronate at a dose of 35 mg orally every week (40 patients) for 6 months in our hospital. The mean age of subjects was 77 years (range, 55–92 years). The primary outcome was duration of back pain. Secondary outcomes included changes in BMD, serum type 1 collagen cross-linked N-telopeptide (NTX), and serum N-terminal propeptide of type 1 collagen (P1NP) from baseline to 6 months. Pain catastrophizing due to back pain was assessed using the Pain Catastrophizing Scale (PCS). The incidences of further vertebral fracture and adverse events were also assessed. Results Pain relief was obtained at a mean of 3.3 weeks with denosumab and 5.4 weeks with alendronate. Pain relief was achieved significantly earlier with denosumab than with alendronate. At 6 months, change in BMD was higher with denosumab (6.1{\%}) than with alendronate (0.8{\%}). No significant differences in changes in NTX and P1NP were observed between groups. Scores for PCS were significantly lower for denosumab than for alendronate. The incidence of further vertebral fractures was 5{\%} with denosumab and 10{\%} with alendronate. Adverse event rates were similar between groups. Conclusions Denosumab enabled earlier pain relief than alendronate and avoided catastrophizing in patients with osteoporotic vertebral fractures after 6 months of treatment.",
author = "Tomoko Tetsunaga and Tomonori Tetsunaga and Keiichiro Nishida and Masato Tanaka and Yoshihisa Sugimoto and Tomoyuki Takigawa and Yoshitaka Takei and Toshihumi Ozaki",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.jos.2016.11.017",
language = "English",
volume = "22",
pages = "230--236",
journal = "Journal of Orthopaedic Science",
issn = "0949-2658",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures

AU - Tetsunaga, Tomoko

AU - Tetsunaga, Tomonori

AU - Nishida, Keiichiro

AU - Tanaka, Masato

AU - Sugimoto, Yoshihisa

AU - Takigawa, Tomoyuki

AU - Takei, Yoshitaka

AU - Ozaki, Toshihumi

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Introduction Denosumab specifically inhibits the receptor activator for nuclear factor-kappa B ligand (RANKL), and prevents osteoporotic fractures. Several reports have analyzed the effects of denosumab and alendronate alone on bone mineral density (BMD) or reduction of fracture risk. The objective of this study was to analyze the effects of antiresorptive osteoporosis pharmacotherapy on pain relief in patients with fresh vertebral fracture. Methods This retrospective, single-center study included 80 patients (10 males, 70 females) with fresh osteoporotic vertebral fractures treated using denosumab at a dose of 60 mg subcutaneously every 6 months (40 patients) or alendronate at a dose of 35 mg orally every week (40 patients) for 6 months in our hospital. The mean age of subjects was 77 years (range, 55–92 years). The primary outcome was duration of back pain. Secondary outcomes included changes in BMD, serum type 1 collagen cross-linked N-telopeptide (NTX), and serum N-terminal propeptide of type 1 collagen (P1NP) from baseline to 6 months. Pain catastrophizing due to back pain was assessed using the Pain Catastrophizing Scale (PCS). The incidences of further vertebral fracture and adverse events were also assessed. Results Pain relief was obtained at a mean of 3.3 weeks with denosumab and 5.4 weeks with alendronate. Pain relief was achieved significantly earlier with denosumab than with alendronate. At 6 months, change in BMD was higher with denosumab (6.1%) than with alendronate (0.8%). No significant differences in changes in NTX and P1NP were observed between groups. Scores for PCS were significantly lower for denosumab than for alendronate. The incidence of further vertebral fractures was 5% with denosumab and 10% with alendronate. Adverse event rates were similar between groups. Conclusions Denosumab enabled earlier pain relief than alendronate and avoided catastrophizing in patients with osteoporotic vertebral fractures after 6 months of treatment.

AB - Introduction Denosumab specifically inhibits the receptor activator for nuclear factor-kappa B ligand (RANKL), and prevents osteoporotic fractures. Several reports have analyzed the effects of denosumab and alendronate alone on bone mineral density (BMD) or reduction of fracture risk. The objective of this study was to analyze the effects of antiresorptive osteoporosis pharmacotherapy on pain relief in patients with fresh vertebral fracture. Methods This retrospective, single-center study included 80 patients (10 males, 70 females) with fresh osteoporotic vertebral fractures treated using denosumab at a dose of 60 mg subcutaneously every 6 months (40 patients) or alendronate at a dose of 35 mg orally every week (40 patients) for 6 months in our hospital. The mean age of subjects was 77 years (range, 55–92 years). The primary outcome was duration of back pain. Secondary outcomes included changes in BMD, serum type 1 collagen cross-linked N-telopeptide (NTX), and serum N-terminal propeptide of type 1 collagen (P1NP) from baseline to 6 months. Pain catastrophizing due to back pain was assessed using the Pain Catastrophizing Scale (PCS). The incidences of further vertebral fracture and adverse events were also assessed. Results Pain relief was obtained at a mean of 3.3 weeks with denosumab and 5.4 weeks with alendronate. Pain relief was achieved significantly earlier with denosumab than with alendronate. At 6 months, change in BMD was higher with denosumab (6.1%) than with alendronate (0.8%). No significant differences in changes in NTX and P1NP were observed between groups. Scores for PCS were significantly lower for denosumab than for alendronate. The incidence of further vertebral fractures was 5% with denosumab and 10% with alendronate. Adverse event rates were similar between groups. Conclusions Denosumab enabled earlier pain relief than alendronate and avoided catastrophizing in patients with osteoporotic vertebral fractures after 6 months of treatment.

UR - http://www.scopus.com/inward/record.url?scp=85013963057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013963057&partnerID=8YFLogxK

U2 - 10.1016/j.jos.2016.11.017

DO - 10.1016/j.jos.2016.11.017

M3 - Article

C2 - 28087216

AN - SCOPUS:85013963057

VL - 22

SP - 230

EP - 236

JO - Journal of Orthopaedic Science

JF - Journal of Orthopaedic Science

SN - 0949-2658

IS - 2

ER -